Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices
- 1 September 2019
- journal article
- research article
- Published by Elsevier BV in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 142, 435-448
- https://doi.org/10.1016/j.ejpb.2019.07.011
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- The Making of a CYP3A Biomarker Panel for Guiding Drug TherapyJournal of Personalized Medicine, 2012
- 4β‐hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humansBritish Journal of Clinical Pharmacology, 2011
- Clinical Relevance of Dissolution Testing in Quality by DesignThe AAPS Journal, 2008
- Intestinal permeability and its relevance for absorption and eliminationXenobiotica, 2007
- Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imagingAlimentary Pharmacology & Therapeutics, 2005
- Assessment of Gastric Acidity of Japanese Subjects over the Last 15 Years.Biological & Pharmaceutical Bulletin, 2001
- The Size of the Unstirred Layer as a Function of the Solute Diffusion CoefficientBiophysical Journal, 1998
- Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.Gut, 1995
- Effect of Diffusion Layer pH and Solubility on the Dissolution Rate of Pharmaceutical Bases and their Hydrochloride Salts I: PhenazopyridineJournal of Pharmaceutical Sciences, 1985
- Investigation of Drug Release from Solids II.**School of Pharmacy, University of Wisconsin, Madison, Wis.Journal of the American Pharmaceutical Association (Scientific ed.), 1958